Who Paid My Doc
Jared Ennis
Interventional Pain Medicine Fayetteville, AR Medical Doctor
NPI 1467539155 CMS profile 339512
4019 N Remington Dr, Fayetteville, AR 72703
General payments
$3,706
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jared Ennis of Fayetteville, AR is reported in the CMS Open Payments database as having received $3,706 across 149 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 48th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $579 | 8 | |
| 2024 | General | $83 | 5 | |
| 2023 | General | $666 | 14 | |
| 2022 | General | $486 | 32 | |
| 2021 | General | $955 | 29 | |
| 2020 | General | $316 | 26 | |
| 2019 | General | $621 | 35 |
Beside peers
- Jared Ennis
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Jared Ennis were reported at $579. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Jared Ennis | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $621 | $684 | $216–$2,079 | $163 |
| 2020 | $316 | $382 | $122–$1,109 | $114 |
| 2021 | $955 | $552 | $167–$1,554 | $132 |
| 2022 | $486 | $605 | $187–$1,924 | $149 |
| 2023 | $666 | $671 | $195–$1,915 | $160 |
| 2024 | $83 | $684 | $206–$1,837 | $164 |
| 2025 | $579 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
1,977
Drug cost
$94,664
Branded share of claims
32%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Buprenorphine | Generic | 113 | $31,651 | |
| Nucynta Tapentadol Hcl | Brand | 13 | $14,414 | |
| Belbuca Buprenorphine Hcl | Brand | 20 | $14,235 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 433 | $9,190 | |
| Oxycontin Oxycodone Hcl | Brand | 11 | $6,398 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 155 | $4,252 | |
| Gabapentin | Generic | 294 | $4,161 | |
| Pregabalin | Generic | 196 | $3,401 | |
| Tramadol Hcl | Generic | 221 | $1,880 | |
| Diclofenac Sodium | Generic | 51 | $1,059 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 55 billing codesPaid by Medicare
$249,360
Medicare patients
397
Services billed
16,509
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Depression | 35% | |
| Ischemic heart disease | 33% | |
| Chronic kidney disease | 29% | |
| Diabetes | 28% | |
| COPD | 21% | |
| Atrial fibrillation | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 202 | 14,483 | $1,474 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 113 | 154 | $835 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 111 | 116 | $783 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
149 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Arkansas
Sameer Jain
Interventional Pain Medicine · Bryant, AR
Ryan Krafft
Interventional Pain Medicine · Mountain Home, AR
Robert Cannon
Interventional Pain Medicine · Fayetteville, AR
Amir Qureshi
Interventional Pain Medicine · Little Rock, AR
Brett Whatcott
Interventional Pain Medicine · Fort Smith, AR
Mohammad Eldeeb
Interventional Pain Medicine · Fort Smith, AR
Related records
Interventional Pain Medicine in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.